• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
EpiVax devises ‘recipe’ for coronavirus vaccine – Providence Business News interview

EpiVax devises ‘recipe’ for coronavirus vaccine – Providence Business News interview

by Elena Iemma | Feb 21, 2020 | News

By Elizabeth Graham -February 21, 2020 2:35 am Find the full story here. Staying current on the frantic pace of the coronavirus outbreak means following reports by major news outlets for most people, but analysts at EpiVax Inc. are more interested in websites that...
EpiVax worked for 21 years to be able to make a vaccine in 24 hours!

EpiVax worked for 21 years to be able to make a vaccine in 24 hours!

by Elena Iemma | Feb 10, 2020 | News

COVID-19 Coverage EpiVax is dedicated to providing continuously updated information concerning COVID-19 vaccine efforts. For all updates, press releases, interviews and more please visit our official COVID-19 page. Click here UPDATE March 16, 2020:   As closures and...
Press Release: EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020

Press Release: EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020

by Sarah Moniz | Dec 27, 2019 | News

Providence, R.I., December 23, 2019 – EpiVax (“EpiVax, Inc.”) continues its record-breaking performance and growth in personnel in 2019 while identifying new milestones to aspire to in 2020. The Business Development team closed 15% more contracts over 2018 and...
Press Release: EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020

Press Release: On Eve of New Decade, EpiVax Re-Pledges Commitment to Improving Health Everywhere

by Sarah Moniz | Dec 20, 2019 | News

Providence, R.I., December 17, 2019 EpiVax, Inc. (“EpiVax”), the home of “fearless science”, announces it will renew their company-wide commitment to “improving human health everywhere” in the new decade (2020). EpiVax has a greater than 20-year tradition of corporate...
Press Release: EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020

Press release: EpiVax’s Novel Tregitope technology offers promising outcomes in the Treatment of Type 1 Diabetes

by Elena Iemma | Nov 6, 2019 | News

Providence, November 6th 2019 EpiVax announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports EpiVax, Inc (“EpiVax”), a pioneer in immunoinformatics innovation, announces the publication of “Therapeutic administration of...
Press Release: EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020

Press Release: Chugai Renews License to EpiVax’s ISPRI In Silico Toolkit for Immunogenicity Assessment

by Elena Iemma | Oct 23, 2019 | News

Announced today, Chugai Pharmaceutical Co., Ltd. (“Chugai”), a member of the Roche Group, will extend the company’s licensed access to the Immunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc....
« Older Entries
Next Entries »

Recent Posts

  • EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction
  • EpiVax Launches AI-Enhanced Analyses for Immunogenicity Prediction 
  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

Manage Consent

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy. 

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}